Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.